Epigenetic factors in cancer development: Polycomb group proteins

Future Oncology

Volumn 7, Issue 1, 2011, Pages 57-75

  Piunti, Andrea ^a   Pasini, Diego ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

cancer; chromatin modifcation; epigenetics; histone modifcation; Polycomb; transcription

Indexed keywords

3 DEAZAADENOSINE; ARF PROTEIN; BMI1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; POLYCOMB GROUP PROTEIN; POLYCOMB REPRESSIVE COMPLEX 1; POLYCOMB REPRESSIVE COMPLEX 2; SINEFUNGIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; BRAIN TUMOR; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CHROMATIN; COMPLEX FORMATION; DIGESTIVE SYSTEM CANCER; DNA METHYLATION; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HISTONE METHYLATION; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA; MOUTH CARCINOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; SENESCENCE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

CHROMATIN ASSEMBLY AND DISASSEMBLY; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MODELS, MOLECULAR; NEOPLASMS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 78650587058     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.157     Document Type: Article

References (192)

1. Simon JA, Kingston RE: Mechanisms of polycomb gene silencing: knowns and unknowns. Nat. Rev. Mol. Cell Biol. 10 (10), 697-708 (2009).
2. Simon J: Locking in stable states of gene expression: transcriptional control during Drosophila development. Curr. Opin. Cell Biol. 7(3), 376-385 (1995).
3. Schwartz YB, Pirrotta V: Polycomb complexes and epigenetic states. Curr. Opin. Cell Biol. 20(3), 266-273 (2008).
4. Orlando V, Paro R: Chromatin multiprotein complexes involved in the maintenance of transcription patterns. Curr. Opin. Genet. Dev. 5(2), 174-179 (1995).
5. Kennison JA: The Polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. Annu. Rev. Genet. 29, 289-303 (1995).
6. Morey L, Helin K: Polycomb group protein-mediated repression of transcription. Trends Biochem. Sci. 35(6), 323-332 (2010).
7. Francis NJ, Saurin AJ, Shao Z, Kingston RE: Reconstitution of a functional core polycomb repressive complex. Mol. Cell. 8(3), 545-556 (2001).
8. King IF, Francis NJ, Kingston RE: Native and recombinant polycomb group complexes establish a selective block to template accessibility to repress transcription in vitro. Mol. Cell Biol. 22(22), 7919-7928 (2002).
9. Shao Z, Raible F, Mollaaghababa R et al.: Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell 98(1), 37-46 (1999).
10. Voncken JW, Roelen BA, Roefs M et al.: Rnf2 (Ring1b) defciency causes gastrulation arrest and cell cycle inhibition. Proc Natl Acad. Sci. USA 100(5), 2468-2473 (2003).
11. van der Lugt NM, Domen J, Linders K et al.: Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 8(7), 757-769 (1994).
12. Cao R, Wang L, Wang H et al.: Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298(5595), 1039-1043 (2002).
13. Czermin B, Melf R, McCabe D, Seitz V, Imhof A, Pirrotta V: Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 111(2), 185-196 (2002).
14. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D: Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16(22), 2893-2905 (2002).
15. Muller J, Hart CM, Francis NJ et al.: Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 111(2), 197-208 (2002).
16. Faust C, Lawson KA, Schork NJ, Thiel B, Magnuson T: The Polycomb-group gene eed is required for normal morphogenetic movements during gastrulation in the mouse embryo. Development 125(22), 4495-4506 (1998).
17. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T: The polycomb-group gene Ezh2 is required for early mouse development. Mol. Cell Biol. 21(13), 4330-4336 (2001).
18. Pasini D, Bracken AP, Jensen MR, Denchi EL, Helin K: Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 23(20), 4061-4071 (2004).
19. Cao R, Wang H, He J, Erdjument-Bromage H, Tempst P, Zhang Y: Role of hPHF1 in H3K27 methylation and Hox gene silencing. Mol. Cell Biol. 28(5), 1862-1872 (2008).
20. Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D: Ezh2 requires PHF1 to effciently catalyze H3 lysine 27 trimethylation in vivo. Mol. Cell Biol. 28(8), 2718-2731 (2008).
21. Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D: Jarid2 and PRC2, partners in regulating gene expression. Genes Dev. 24(4), 368-380 (2010).
22. Shen X, Kim W, Fujiwara Y et al.: Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell 139(7), 1303-1314 (2009).
23. Walker E, Chang WY, Hunkapiller J et al.: Polycomb-like 2 associates with PRC2 and regulates transcriptional networks during mouse embryonic stem cell self-renewal and differentiation. Cell Stem Cell 6(2), 153-166 (2010).
24. Landeira D, Sauer S, Poot R et al.: Jarid2 is a PRC2 component in embryonic stem cells required for multilineage differentiation and recruitment of PRC1 and RNA polymerase II to developmental regulators. Nat. Cell Biol. 12(6), 618-624 (2010).
25. Pasini D, Cloos PA, Walfridsson J et al.: JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature 464(7286), 306-310 (2010).
26. Peng JC, Valouev A, Swigut T et al.: Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 139(7), 1290-1302 (2009).
27. Bernstein BE, Mikkelsen TS, Xie X et al.: A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125(2), 315-326 (2006).
28. Boyer LA, Plath K, Zeitlinger J et al.: Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441(7091), 349-353 (2006).
29. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K: Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20(9), 1123-1136 (2006).
30. Lee TI, Jenner RG, Boyer LA et al.: Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125(2), 301-313 (2006).
31. Mikkelsen TS, Ku M, Jaffe DB et al.: Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448(7153), 553-560 (2007).
32. Mohn F, Weber M, Rebhan M et al.: Lineage-specifc polycomb targets and de novo DNA methylation defne restriction and potential of neuronal progenitors. Mol. Cell. 30(6), 755-766 (2008).
33. Squazzo SL, O'Geen H, Komashko VM et al.: Suz12 binds to silenced regions of the genome in a cell-type-specifc manner. Genome Res. 16(7), 890-900 (2006).
34. Luger K: Structure and dynamic behavior of nucleosomes. Curr. Opin. Genet. Dev. 13(2), 127-135 (2003).
35. Jenuwein T, Allis CD: Translating the histone code. Science 293(5532), 1074-1080 (2001).
36. Hansen KH, Helin K: Epigenetic inheritance through self-recruitment of the polycomb repressive complex 2. Epigenetics 4(3), 133-138 (2009).
37. Waddington CH: The epigenotype. Endeavour 1, 18-20 (1942).
38. Levenson JM, Sweatt JD: Epigenetic mechanisms in memory formation. Nat. Rev. Neurosci. 6(2), 108-118 (2005).
39. Keverne B: Monoallelic gene expression and mammalian evolution. Bioessays 31(12), 1318-1326 (2009).
40. Sparmann A, van Lohuizen M: Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6(11), 846-856 (2006).
41. Cao R, Zhang Y: SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol. Cell 15(1), 57-67 (2004).
42. Cao R, Tsukada Y, Zhang Y: Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol. Cell 20(6), 845-854 (2005).
43. Bernstein E, Duncan EM, Masui O, Gil J, Heard E, Allis CD: Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol. Cell. Biol. 26(7), 2560-2569 (2006).
44. Wang H, Wang L, Erdjument-Bromage H et al.: Role of histone H2A ubiquitination in Polycomb silencing. Nature 431(7010), 873-878 (2004).
45. Francis NJ, Kingston RE, Woodcock CL: Chromatin compaction by a polycomb group protein complex. Science 306(5701), 1574-1577 (2004).
46. Kuzmichev A, Jenuwein T, Tempst P, Reinberg D: Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol. Cell 14(2), 183-193 (2004).
47. Kuzmichev A, Margueron R, Vaquero A et al.: Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl Acad. Sci. USA 102(6), 1859-1864 (2005).
48. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100(1), 57-70 (2000).
49. Mantovani A: Cancer: infaming metastasis. Nature 457(7225), 36-37 (2009).
50. Carver BS, Pandolf PP: Mouse modeling in oncologic preclinical and translational research. Clin. Cancer Res. 12(18), 5305-5311 (2006).
51. Degenhardt K, White E: A mouse model system to genetically dissect the molecular mechanisms regulating tumorigenesis. Clin. Cancer Res. 12 (18), 5298-5304 (2006).
52. Fomchenko EI, Holland EC: Mouse models of brain tumors and their applications in preclinical trials. Clin. Cancer Res. 12(18), 5288-5297 (2006).
53. Olive KP, Tuveson DA: The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin. Cancer Res. 12 (18), 5277-5287 (2006).
54. Rangarajan A, Weinberg RA: Opinion: comparative biology of mouse versus human cells: modeling human cancer in mice. Nat. Rev. Cancer. 3(12), 952-959 (2003).
55. Karakosta A, Golias C, Charalabopoulos A, Peschos D, Batistatou A, Charalabopoulos K: Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia. J. Exp. Clin. Cancer Res. 24(4), 505-514 (2005).
56. Krivtsov AV, Armstrong SA: MLL translocations, histone modifcations and leukaemia stem-cell development. Nat. Rev. Cancer 7(11), 823-833 (2007).
57. Bracken AP, Helin K: Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 9(11), 773-784 (2009).
58. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A: Identifcation of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65(5), 737-752 (1991).
59. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM: Novel zinc fnger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 65(5), 753-763 (1991).
60. Varambally S, Dhanasekaran SM, Zhou M et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907), 624-629 (2002).
61. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K: EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplifed in cancer. EMBO J. 22(20), 5323-5335 (2003).
62. Bernard D, Martinez-Leal JF, Rizzo S et al.: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 24(36), 5543-5551 (2005).
63. Van Leenders GJ, Dukers D, Hessels D et al.: Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur. Urol. 52(2), 455-463 (2007).
64. Karanikolas BD, Figueiredo ML, Wu L: Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate 70(6), 675-688 (2010).
65. Yu J, Cao Q, Mehra R et al.: Integrative genomics analysis reveals silencing of β-adrenergic signaling by Polycomb in prostate cancer. Cancer Cell 12(5), 419-431 (2007).
66. Karanikolas BD, Figueiredo ML, Wu L: Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol. Cancer Res. 7(9), 1456-1465 (2009).
67. Wang W, Yuasa T, Tsuchiya N et al.: The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical signifcance. Int. J. Cancer 125(12), 2836-2843 (2009).
68. Guo WJ, Datta S, Band V, Dimri GP: Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol. Biol. Cell. 18(2), 536-546 (2007).
69. Kajiume T, Ninomiya Y, Ishihara H, Kanno R, Kanno M: Polycomb group gene mel-18 modulates the self-renewal activity and cell cycle status of hematopoietic stem cells. Exp. Hematol. 32(6), 571-578 (2004).
70. Park IK, Qian D, Kiel M et al.: Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423 (6937), 302-305 (2003).
71. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV: Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 5(16), 1886-1901 (2006).
72. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T: The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplifed in late-stage prostate cancer. Genes Chromosomes Cancer 45(7), 639-645 (2006).
73. Varambally S, Cao Q, Mani RS et al.: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908), 1695-1699 (2008).
74. Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M: The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 26(31), 4590-4595 (2007).
75. Min J, Zaslavsky A, Fedele G et al.: An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 16(3), 286-294 (2010).
76. Yu J, Rhodes DR, Tomlins SA et al.: A Polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67(22), 10657-10663 (2007).
77. Furnari FB, Fenton T, Bachoo RM et al.: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21(21), 2683-2710 (2007).
78. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G: BMI1 sustains human glioblastoma multiforme stem cell renewal. J. Neurosci. 29(28), 8884-8896 (2009).
79. Godlewski J, Nowicki MO, Bronisz A et al.: Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 68(22), 9125-9130 (2008).
80. Korur S, Huber RM, Sivasankaran B et al.: GSK3β regulates differentiation and growth arrest in glioblastoma. PLoS One 4(10), E7443 (2009).
81. Suva ML, Riggi N, Janiszewska M et al.: EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69(24), 9211-9218 (2009).
82. Bruggeman SW, Hulsman D, Tanger E et al.: Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell. 12 (4), 328-341 (2007).
83. Hayry V, Tanner M, Blom T et al.: Copy number alterations of the polycomb gene BMI1 in gliomas. Acta Neuropathol. 116(1), 97-102 (2008).
84. Ochiai H, Takenobu H, Nakagawa A et al.: Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bβ and TSLC1 in neuroblastoma. Oncogene 29(18), 2681-2690 (2010).
85. Bruggeman SW, Hulsman D, van Lohuizen M: Bmi1 defcient neural stem cells have increased integrin dependent adhesion to self-secreted matrix. Biochim. Biophys. Acta 1790(5), 351-360 (2009).
86. Wiederschain D, Chen L, Johnson B et al.: Contribution of Polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis. Mol. Cell Biol. 27(13), 4968-4979 (2007).
87. Collett K, Eide GE, Arnes J et al.: Expression of enhancer of zeste homologue 2 is signifcantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 12(4), 1168-1174 (2006).
88. Kleer CG, Cao Q, Varambally S et al.: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad. Sci. USA 100(20), 11606-11611 (2003).
89. Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG: Identifcation of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res. 66(8), 4095-4099 (2006).
90. Silva J, Garcia JM, Pena C et al.: Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin. Cancer Res. 12(23), 6929-6936 (2006).
91. Lee JY, Jang KS, Shin DH et al.: Mel-18 negatively regulates INK4a/ARF-independent cell cycle progression via Akt inactivation in breast cancer. Cancer Res. 68(11), 4201-4209 (2008).
92. Hoenerhoff MJ, Chu I, Barkan D et al.: BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 28(34), 3022-3032 (2009).
93. Puppe J, Drost R, Liu X et al.: BRCA1-defcient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 11(4), R63 (2009).
94. Li X, Gonzalez ME, Toy K, Filzen T, Merajver SD, Kleer CG: Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am. J. Pathol. 175(3), 1246-1254 (2009).
95. Ben-Porath I, Thomson MW, Carey VJ et al.: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40(5), 499-507 (2008).
96. Gupta RA, Shah N, Wang KC et al.: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464(7291), 1071-1076 (2010).
97. Rinn JL, Kertesz M, Wang JK et al.: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129(7), 1311-1323 (2007).
98. Lessard J, Schumacher A, Thorsteinsdottir U, van Lohuizen M, Magnuson T, Sauvageau G: Functional antagonism of the Polycomb-group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev. 13(20), 2691-2703 (1999).
99. Su IH, Basavaraj A, Krutchinsky AN et al.: Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4(2), 124-131 (2003).
100. Bea S, Tort F, Pinyol M et al.: BMI1 gene amplifcation and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 61(6), 2409-2412 (2001).
101. Raaphorst FM, van Kemenade FJ, Blokzijl T et al.: Coexpression of BMI-1 and EZH2 Polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am. J. Pathol. 157(3), 709-715 (2000).
102. van Kemenade FJ, Raaphorst FM, Blokzijl T et al.: Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97(12), 3896-3901 (2001).
103. Visser HP, Gunster MJ, Kluin-Nelemans HC et al.: The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol. 112(4), 950-958 (2001).
104. van Galen JC, Muris JJ, Oudejans JJ et al.: Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL. J. Clin. Pathol. 60(2), 167-172 (2007).
105. Alkema MJ, Jacobs H, van Lohuizen M, Berns A: Pertubation of B and T cell development and predisposition to lymphomagenesis in Emu Bmi1 transgenic mice require the Bmi1 RING fnger. Oncogene 15(8), 899-910 (1997).
106. Sander S, Bullinger L, Klapproth K et al.: MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112(10), 4202-4212 (2008).
107. Morin RD, Johnson NA, Severson TM et al.: Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42(2), 181-185 (2010).
108. Scott CL, Gil J, Hernando E et al.: Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad. Sci. USA 104 (13), 5389-5394 (2007).
109. Redner RL: Variations on a theme: the alternate translocations in APL. Leukemia 16(10), 1927-1932 (2002).
110. Villa R, Pasini D, Gutierrez A et al.: Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11(6), 513-525 (2007).
111. Boukarabila H, Saurin AJ, Batsche E et al.: The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev. 23(10), 1195-1206 (2009).
112. Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A: Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia 21(5), 1116-1122 (2007).
113. Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV: The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110(1), 380-383 (2007).
114. Sawa M, Yamamoto K, Yokozawa T et al.: BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int. J. Hematol. 82(1), 42-47 (2005).
115. Lessard J, Sauvageau G: Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423(6937), 255-260 (2003).
116. Fiskus W, Wang Y, Sreekumar A et al.: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114(13), 2733-2743 (2009).
117. Tokimasa S, Ohta H, Sawada A et al.: Lack of the Polycomb-group gene rae28 causes maturation arrest at the early B-cell developmental stage. Exp. Hematol. 29(1), 93-103 (2001).
118. Ernst T, Chase AJ, Score J et al.: Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42(8), 722-726 (2010).
119. Nikoloski G, Langemeijer SM, Kuiper RP et al.: Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42(8), 665-667 (2010).
120. Breuer RH, Snijders PJ, Smit EF et al.: Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6(6), 736-743 (2004).
121. Breuer RH, Snijders PJ, Sutedja GT et al.: Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 48(3), 299-306 (2005).
122. Dovey JS, Zacharek SJ, Kim CF, Lees JA: Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc. Natl Acad. Sci. USA 105 (33), 11857-11862 (2008).
123. Hussain M, Rao M, Humphries AE et al.: Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res. 69(8), 3570-3578 (2009).
124. Sasaki M, Ikeda H, Itatsu K et al.: The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab. Invest. 88(8), 873-882 (2008).
125. Steele JC, Torr EE, Noakes KL et al.: The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br. J. Cancer 95(9), 1202-1211 (2006).
126. Kang MK, Kim RH, Kim SJ et al.: Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br. J. Cancer 96(1), 126-133 (2007).
127. Kidani K, Osaki M, Tamura T et al.: High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol. 45(1), 39-46 (2009).
128. Cai GH, Wang K, Miao Q, Peng YS, Chen XY: Expression of polycomb protein EZH2 in multistage tissues of gastric carcinogenesis. J. Dig Dis. 11(2), 88-93 (2010).
129. Li W, Li Y, Tan Y, Ma K, Cui J: Bmi-1 is critical for the proliferation and invasiveness of gastric carcinoma cells. J. Gastroenterol. Hepatol. 25(3), 568-575 (2010).
130. Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M: Clinical signifcance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur. J. Surg. Oncol. 31(4), 376-380 (2005).
131. Tateishi K, Ohta M, Kanai F et al.: Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. Clin. Cancer Res. 12(23), 6960-6966 (2006).
132. Sasaki H, Setoguchi T, Matsunoshita Y, Gao H, Hirotsu M, Komiya S: The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth. Oncol. Rep. 23(3), 677-684 (2010).
133. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, Ergenekon E: Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol. Int. 75(3), 252-257 (2005).
134. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ: Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res. 11(24 Pt 1), 8570-8576 (2005).
135. Shafaroudi AM, Mowla SJ, Ziaee SA, Bahrami AR, Atlasi Y, Malakootian M: Overexpression of BMI1, a Polycomb group repressor protein, in bladder tumors: a preliminary report. Urol. J. 5(2), 99-105 (2008).
136. Weikert S, Christoph F, Kollermann J et al.: Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int. J. Mol. Med. 16(2), 349-353 (2005).
137. McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD: Expression of polycomb group protein EZH2 in nevi and melanoma. J. Cutan. Pathol. 34(8), 597-600 (2007).
138. Bachmann IM, Puntervoll HE, Otte AP, Akslen LA: Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod. Pathol. 21(5), 583-590 (2008).
139. Song LB, Li J, Liao WT et al.: The Polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Invest. 119(12), 3626-3636 (2009).
140. Friedman JM, Liang G, Liu CC et al.: The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 69(6), 2623-2629 (2009).
141. Hinz S, Kempkensteffen C, Weikert S et al.: EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superfcial transitional cell carcinoma of the bladder. Tumour Biol. 28(3), 151-157 (2007).
142. Karamitopoulou E, Pallante P, Zlobec I et al.: Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur. J. Cancer 46(8), 1438-1444 (2010).
143. Deshpande AM, Akunowicz JD, Reveles XT et al.: PHC3, a component of the hPRC-H complex, associates with E2F6 during G0 and is lost in osteosarcoma tumors. Oncogene 26(12), 1714-1722 (2007).
144. Koontz JI, Soreng AL, Nucci M et al.: Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad. Sci. USA 98(11), 6348-6353 (2001).
145. Micci F, Panagopoulos I, Bjerkehagen B, Heim S: Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res. 66(1), 107-112 (2006).
146. Li H, Wang J, Mor G, Sklar J: A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science 321(5894), 1357-1361 (2008).
147. Ringrose L, Paro R: Polycomb/Trithorax response elements and epigenetic memory of cell identity. Development 134(2), 223-232 (2007).
148. Ringrose L, Rehmsmeier M, Dura JM, Paro R: Genome-wide prediction of Polycomb/Trithorax response elements in Drosophila melanogaster. Dev. Cell 5(5), 759-771 (2003).
149. Negre N, Hennetin J, Sun LV et al.: Chromosomal distribution of PcG proteins during Drosophila development. PLoS Biol. 4(6), E170 (2006).
150. Sing A, Pannell D, Karaiskakis A et al.: A vertebrate Polycomb response element governs segmentation of the posterior hindbrain. Cell 138(5), 885-897 (2009).
151. Woo CJ, Kharchenko PV, Daheron L, Park PJ, Kingston RE: A region of the human HOXD cluster that confers polycomb-group responsiveness. Cell 140(1), 99-110 (2009).
152. Pasini D, Hansen KH, Christensen J, Agger K, Cloos PA, Helin K: Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and Polycomb-Repressive Complex 2. Genes Dev. 22(10), 1345-1355 (2008).
153. Herranz N, Pasini D, Diaz VM et al.: Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol. Cell Biol. 28(15), 4772-4781 (2008).
154. Shi B, Liang J, Yang X et al.: Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol. Cell Biol. 27(14), 5105-5119 (2007).
155. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT: Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 322(5902), 750-756 (2008).
156. Yap KL, Li S, Munoz-Cabello AM et al.: Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol. Cell. 38(5), 662-674 (2010).
157. Tsai MC, Manor O, Wan Y et al.: Long noncoding RNA as modular scaffold of histone modifcation complexes. Science 329(5992), 689-693 (2010).
158. Bracken AP, Kleine-Kohlbrecher D, Dietrich N et al.: The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21(5), 525-530 (2007).
159. Dietrich N, Bracken AP, Trinh E et al.: Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. EMBO J. 26(6), 1637-1648 (2007).
160. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397(6715), 164-168 (1999).
161. Gil J, Peters G: Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol. 7(9), 667-677 (2006).
162. Gil J, Bernard D, Martinez D, Beach D: Polycomb CBX7 has a unifying role in cellular lifespan. Nat. Cell Biol. 6(1), 67-72 (2004).
163. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M: Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13(20), 2678-2690 (1999).
164. Bruggeman SW, Valk-Lingbeek ME, van der Stoop PP et al.: Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-defcient mice. Genes Dev. 19(12), 1438-1443 (2005).
165. Chen H, Gu X, Su IH et al.: Polycomb protein Ezh2 regulates pancreatic β-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes Dev. 23(8), 975-985 (2009).
166. Ezhkova E, Pasolli HA, Parker JS et al.: Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specifc stem cells. Cell 136(6), 1122-1135 (2009).
167. Liu J, Cao L, Chen J et al.: Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 459 (7245), 387-392 (2009).
168. Vonlanthen S, Heighway J, Altermatt HJ et al.: The bmi-1 oncoprotein is differentially expressed in non-small-cell lung cancer and correlates with INK4A-ARF locus expression. Br. J. Cancer 84(10), 1372-1376 (2001).
169. Dukers DF, van Galen JC, Giroth C et al.: Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am. J. Pathol. 164(3), 873-881 (2004).
170. Young NP, Jacks T: Tissue-specifc p19Arf regulation dictates the response to oncogenic K-ras. Proc. Natl Acad. Sci. USA 107(22), 10184-10189 (2010).
171. Douglas D, Hsu JH, Hung L et al.: BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res. 68(16), 6507-6515 (2008).
172. Christman JK: 5-Azacytidine and 5-aza-2́-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21(35), 5483-5495 (2002).
173. Klose RJ, Bird AP: Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31(2), 89-97 (2006).
174. Kangaspeska S, Stride B, Metivier R et al.: Transient cyclical methylation of promoter DNA. Nature 452(7183), 112-115 (2008).
175. Metivier R, Gallais R, Tiffoche C et al.: Cyclical DNA methylation of a transcriptionally active promoter. Nature 452(7183), 45-50 (2008).
176. Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR: DNA demethylation in zebrafsh involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 135(7), 1201-1212 (2008).
177. Tahiliani M, Koh KP, Shen Y et al.: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929), 930-935 (2009).
178. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002).
179. Laird PW: Cancer epigenetics. Hum. Mol. Genet. 14, R65-R76 (2005).
180. Schwabe M, Lubbert M: Epigenetic lesions in malignant melanoma. Curr. Pharm. Biotechnol. 8(6), 382-387 (2007).
181. Vire E, Brenner C, Deplus R et al.: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439(7078), 871-874 (2006).
182. Paul TA, Bies J, Small D, Wolff L: Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 115(15), 3098-3108 (2010).
183. Reynolds PA, Sigaroudinia M, Zardo G et al.: Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J. Biol. Chem. 281 (34), 24790-24802 (2006).
184. McGarvey KM, Greene E, Fahrner JA, Jenuwein T, Baylin SB: DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer Res. 67(11), 5097-5102 (2007).
185. Mohammad HP, Cai Y, McGarvey KM et al.: Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specifc DNA hypermethylation. Cancer Res. 69(15), 6322-6330 (2009).
186. Kondo Y, Shen L, Cheng AS et al.: Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 40(6), 741-750 (2008).
187. Ohm JE, McGarvey KM, Yu X et al.: A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 39(2), 237-242 (2007).
188. Schlesinger Y, Straussman R, Keshet I et al.: Polycomb-mediated methylation on Lys27 of histone H3 premarks genes for de novo methylation in cancer. Nat. Genet. 39(2), 232-236 (2007).
189. Tan J, Yang X, Zhuang L et al.: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007).
190. Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q: Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol. Cancer Ther. 8(12), 3191-3202 (2009).
191. Miranda TB, Cortez CC, Yoo CB et al.: DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8(6), 1579-1588 (2009).
192. Margueron R, Justin N, Ohno K et al.: Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 461(7265), 762-767 (2009).